ArticleLeukemia & lymphoma2019
Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study.
Article in Leukemia & lymphoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Priorities for Rural Lymphoma Survivors: A Qualitative Study.Clinical lymphoma, myeloma & leukemia · 2020Trial
- Socioeconomic disparities in survival among follicular lymphoma patients.Scientific reports · 2026Article
- Sustained improvement in survival for primary ocular adnexal lymphoma from 2005 to 2024 by model-based period analysis.Discover oncology · 2026Article
- Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma.Clinical lymphoma, myeloma & leukemia · 2026Article
- Response-Based Approach for Pediatric Hodgkin Lymphoma in Nations with Restricted Resources.International journal of hematology-oncology and stem cell research · 2024Article
- The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.American journal of hematology · 2024Article
- Barriers to accessing cellular therapy for patients receiving care in community practices.Hematology. American Society of Hematology. Education Program · 2023Article
- Sequencing therapy in relapsed DLBCL.Hematology. American Society of Hematology. Education Program · 2022Article
- Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors.Cancer epidemiology · 2021Article
- Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B-Cell Lymphoma.The Laryngoscope · 2021Article
- Clinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System.Clinical lymphoma, myeloma & leukemia · 2021Article
- Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature.Mediterranean journal of hematology and infectious diseases · 2021Review
- Article
- Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region.Clinical lymphoma, myeloma & leukemia · 2019Article
- Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.Expert review of hematology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
We examined 83,108 patients with diffuse large B-cell lymphoma (DLBCL) and 43,393 patients with follicular lymphoma (FL) to investigate disparities related to geographic population density, stratified as rural, urban, or metropolitan. We found that urban and rural patients less commonly had private insurance and high socioeconomic status. Urban and rural DLBCL patients were more likely to receive treatment within 14 days of diagnosis (OR 0.93, 95% confidence interval [CI] 0.89-0.98; and OR 0.81, 95% CI 0.72-0.91) while urban FL patients were more likely to have treatment >14 days after diagnosis (OR 1.08, 95% CI 1.01-1.16). Multivariable analyses demonstrated that rural and urban patients had worse overall survival with DLBCL (hazard ratio [HR] 1.09; 95% CI 1-1.19 and HR 1.08; 95% CI 1.04-1.11) and FL (HR 1.11; 95% CI 1.04-1.18 and HR 1.2; 95% CI 1.02-1.41), respectively, suggesting needs for focused study and interventions for these populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.